1. Modern execs sell stock amid coronavirus vaccine news  New York Daily News
  2. Experimental coronavirus vaccine hits new milestone  Yahoo Finance
  3. Moderna unveiled encouraging coronavirus vaccine results. Then top execs dumped nearly $30 million of stock  CNN
  4. Column: When we have a coronavirus vaccine, will we want to use it?  Chicago Tribune
  5. A Vaccine With a Poison Pill  Bloomberg
  6. View Full Coverage on Google News
As Moderna reported encouraging news on a vaccine trial, top executives moved their stock.As Moderna reported encouraging news on a vaccine trial, top executives moved their stock.

Modern execs sell stock amid coronavirus vaccine news - New York Daily News

Moderna's share price skyrocketed after it released promising results from its vaccine trial Monday, sparking hope that a vaccine could be available January.Moderna's share price skyrocketed after it released promising results from its vaccine trial Monday, sparking hope that a vaccine could be available January.

Moderna executives offloaded nearly $30 million of stocks a day after unveiling coronavirus vaccine | Daily Mail Online

1/VACCINE RACE1/VACCINE RACE

Take Five: Coronavirus vaccine race is on - Reuters

Reuters report on the vaccine trial The US plans a massive round of phase 2 vaccine trials in an effort to speed up the timeline for vaccine development to have a mass candidate ready by year-end. By Adam ButtonReuters report on the vaccine trial The US plans a massive round of phase 2 vaccine trials in an effort to speed up the timeline for vaccine development to have a mass candidate ready by year-end.

US will test vaccines on more than 100,000 people starting in July - report

Bloomberg - Are you a robot?

We may be harder to persuade than we were in the polio vaccine days.We may be harder to persuade than we were in the polio vaccine days.

Column: When we have a coronavirus vaccine, will we want to use it? - Chicago Tribune

The speed in developing vaccines for widespread testing this summer is impressive, but running trials involving tens of thousands of people will be an immense undertaking.The speed in developing vaccines so far is impressive, but running trials this summer involving tens of thousands of people will be a tough challenge.

Op-Ed: Fast coronavirus vaccine could bring problems - Los Angeles Times

Will vaccine for COVID-19 play into the developing narrative of seeing a shift of technological and scientific innovation from the Global North to the Global South? Or will the race simply re-instate the Cold War notion of Western world dominance?Will COVID vaccine shift narrative in technological & scientific innovation from Global North to Global South? 

Will India Overtake China As Global Power If It Wins the Vaccine Race? | OPINION

If there is a silver lining to the flawed U.S. response to the coronavirus pandemic, it is this: The relatively high number of new cases being diagnosed daily — upward of 20,000 — will make it easier to test new vaccines.If there is a silver lining to the flawed U.S. response to the coronavirus pandemic, it is this: The relatively high number of new cases being diagnosed daily — upward of 20,000 — will make it easier to test new vaccines.

Analysis: Get ready for the vaccine — they’re never simple

“The U.S. government is providing billions to the drug companies to develop a COVID-19 vaccine. Once that vaccine is approved by the FDA, it must be available to all for free. We've already paid for it. This is not a time for pharmaceutical industry profiteering.”

Bernie Sanders on Twitter: "The U.S. government is providing billions to the drug companies to develop a COVID-19 vaccine. Once that vaccine is approved by the FDA, it must be available to all for free. We've already paid for it. This is not a time for pharmaceutical industry profiteering."

“Thank you to this science teacher who came to my aid when I was confronted by an angry constituent upset by my support of vaccines as I handed out #ppe this morning! In this era of #covid19, science-based policy is… https://t.co/JupnwqxOeU”

Senator Brad Hoylman on Twitter: "Thank you to this science teacher who came to my aid when I was confronted by an angry constituent upset by my support of vaccines as I handed out #ppe this morning! In this era of #covid19, science-based policy is… https://t.co/JupnwqxOeU"

“Worth reading on covid vaccines: be ready for something more like a flu vaccine, than the smallpox one. (But we mustn't let the perfect be the enemy of the good) https://t.co/zeIYtFifK4 via @statnews”

Evan Davis on Twitter: "Worth reading on covid vaccines: be ready for something more like a flu vaccine, than the smallpox one. (But we mustn't let the perfect be the enemy of the good) https://t.co/zeIYtFifK4 via @statnews"

“This is what our government is paying to develop a COVID19 vaccine: - $1.2 billion to AstraZeneca - $483 million to Moderna - $500 million to Johnson & Johnson - $30 million to Sanofi Once a vaccine is approved by the FDA, it must be available to all for free. No profiteering.”

Bernie Sanders on Twitter: "This is what our government is paying to develop a COVID19 vaccine: - $1.2 billion to AstraZeneca - $483 million to Moderna - $500 million to Johnson & Johnson - $30 million to Sanofi Once a vaccine is approved by the FDA, it must be available to all for free. No profiteering."

Read the latest Granada stories, Liverpool School of Tropical Medicine taking part Covid-19 vaccine trials on ITV News, videos, stories and all the latest Granada newsLiverpool School of Tropical Medicine has begun recruiting frontline health and social care workers to take part in a COVID-19 vaccine trial. The school has been selected as one of the UK sites for phase III of the University of Oxford’s COVID-19 vaccine clinical trial. Led by Professor Andrew Pollard from the Oxford Vaccine Group, the trial will study the efficacy and safety of the candidate COVID-19 vaccine in healthy adults. The team at LSTM, under the leadership of Professor Daniela Ferreira: “We were delighted to be asked by Professor Pollard to be a site for the study. From the vaccine candidates we have in therace against COVID, the Oxford vaccine is progressing at an amazing pace. If the trials demonstrate this vaccine is safe and effective there will be millions of doses already produced that could be quickly administered. The potential impact of this could be massive on two fronts, by saving millions of lives not only in the UK, but also globally, as well as the economic benefits of allowing society to get back to normal without the risk of future COVID-19 peaks.”

Liverpool School of Tropical Medicine taking part Covid-19 vaccine trials | Granada - ITV News

The desperate hunt for treatments and vaccines has changed how researchers, regulators, drug companies like Moderna, investors and journalists do their jobs.The desperate hunt for treatments and vaccines has changed how researchers, regulators, drug companies like Moderna, investors and journalists do their jobs.

In a recent poll by Reuters and Ipsos, 1 out of 4 of Americans had little or no interest in a COVID-19 vaccine. Fears stem from 'Operation Warp Speed' sacrificing safety for speed. 'Many experts believe a fully tested, government-approved vaccine will not be widely available until mid-2021 at the earliest.'

Americans express fears surrounding a COVID-19 vaccine | World Economic Forum

Moderna has seen its market cap increase from $9 billion to over $25 billion in the past two months. While it may be justified due to its Covid-19 trails, a lot has to go right to justify its stratospheric valuation.Moderna has seen its market cap increase from $9 billion to over $25 billion in the past two months. While it may be justified due to its Covid-19 trails, a lot has to go right to justify its stratospheric valuation.

Buyer Beware: Covid-19 Vaccine Maker Moderna Is Valued In The Stratosphere

The United States plans a massive testing effort involving more than 100,000 volunteers and a half dozen or so of the most promising vaccine ...The United States plans a massive testing effort involving more than 100,000 volunteers and a half dozen or so of the most promising vaccine ...

US plans massive COVID-19 vaccine testing effort to meet year-end deadline - CNA

Vaccine goal tailor-made for China's biotech firms - World - Chinadaily.com.cn

Today's Covid-19 developments include news about a New Zealand vaccine venture, a lauded celebrity cat, problems getting shearing gangs, and a warning against Trump's favoured medicine of choice.Today's Covid-19 developments include news about a New Zealand vaccine venture, a lauded celebrity cat, problems getting shearing gangs, and a warning against Trump's favoured medicine of choice.

Covid-19: What happened in NZ and around the world on 23 May | RNZ News

Moderna’s initial coronavirus vaccine results are promising -- but confirmation in more trial participants is key.Moderna’s initial coronavirus vaccine results are promising -- but confirmation in more trial participants is key.

Moderna Shares Surged 20% on Coronavirus Vaccine Data. Here's What May Drive Them Higher. | The Motley Fool

Vincent Chen wrote that it was “hard to pick winners” among the many Covid-19 vaccine programs, and that a vaccine wouldn’t be widely available until later next year.Vincent Chen wrote that it was “hard to pick winners” among the many Covid-19 vaccine programs, and that a vaccine wouldn’t be widely available until later next year.

A Covid-19 Vaccine Could Be Ready Late This Year, Bernstein Analyst Says - Barron's

Early progress has been reported on several vaccine efforts, as scientists around the world scramble to test ways to protect people from the coronavirus.Early progress has been reported on several vaccine efforts, as scientists around the world scramble to test ways to protect people from the coronavirus.

Early morning on May 18, Moderna, a biotechnology company, revealed the preliminary findings for the much anticipated phase I trial of an mRNA COVID-19 vaccine. The information sent Moderna’s stock soaring by more than 20% and helped fuel a rally on…Early morning on May 18, Moderna, a biotechnology company, revealed the preliminary findings for the much anticipated phase I trial of an mRNA COVID-19 vaccine. The information sent Moderna’s stock soaring by more than 20% and helped fuel a rally on…

The first coronavirus vaccine trial was "promising," but what does that really mean?

An early trial of a prospective COVID-19 vaccine that will soon be tested on Canadians has found it to be safe and effective at prompting an immune response. A study published Friday in the Lancet says the formulation from China’s CanSino Biologics Inc. needs more trials to determine whether it can actually protect against SARS-CoV-2, […]

Early results promising for potential COVID-19 vaccine to be tested on Canadians - CityNews Toronto

Biotech stocks are in the spotlight in 2020, with the race to develop testing, treatment and a vaccine for Covid-19 driving rapid growth.Biotech stocks are in the spotlight in 2020, with the race to develop testing, treatment and a vaccine for Covid-19 driving rapid growth.

7 Top-Rated Biotech Stocks to Buy on the Hunt for a Vaccine | InvestorPlace

With massive disruptions to global immunisation programmes, experts fear that the developing world will not be able to get COVID-19 vaccine even once its ready.With massive disruptions to global immunisation programmes, experts fear that the developing world will not be able to get COVID-19 vaccine even once its ready.

COVID-19: Experts fear much of developing world may not get a vaccine even once its ready - Republic World

BANGKOK - Thailand on Saturday began testing a vaccine against the coronavirus on monkeys after positive trials in mice, an official said.BANGKOK - Thailand on Saturday began testing a vaccine against the coronavirus on monkeys after positive trials in mice, an official said.

Coronavirus vaccine: Thailand begins COVID-19 vaccine trials on monkeys - Times of India

Austin's own Tito's Handmade Vodka has provided a million-dollar grant to Baylor College of Medicine as they work to research a vaccine for COVID-19.Austin's own Tito's Handmade Vodka has provided a million-dollar grant to Baylor College of Medicine as they work to research a vaccine for COVID-19.

Tito's Handmade Vodka gives $1 million for COVID-19 vaccine research | WBNS-10TV Columbus, Ohio | Columbus News, Weather & Sports

404 Not Found

NoCookies | The Australian

Four of the biotech's top executives netted a total of $30 million since positive results for a coronavirus vaccine were touted.Four of the biotech's top executives netted a total of $30 million since positive results for a coronavirus vaccine were touted.

Moderna CEO and other execs made millions on vaccine announcement - CBS News

Almost 20% of people surveyed by YouGov said they wouldn't be willing to be vaccinated against coronavirus.Almost 20% of people surveyed by YouGov said they wouldn't be willing to be vaccinated against coronavirus.

Coronavirus vaccine: Only 55% of Americans would get immunized, survey - Business Insider

In this week’s interview, Dr. Peter Hotez discusses his alarm that the Houston area doesn’t yet have the public-health troops it needs to reopen, his worries about the anti-vaccine movement, and a surprising new funder of his research — Tito’s Vodka. <p>In this week’s interview, Dr. Peter Hotez discusses his alarm that the Houston area doesn’t yet have the public-health troops it needs to reopen, his worries about the anti-vaccine movement, and a surprising new funder of his research — Tito’s Vodka.</p>

Vaccine expert Peter Hotez reveals 3 things to help Houston reopen, avoid second surge of COVID-19 - HoustonChronicle.com

President Donald Trump dismissed the idea of a new series of lockdowns should the world’s largest economy experience a second wave of coronavirus infections, which continue to level off as parts of the country reopen.President Donald Trump dismissed the idea of a new series of lockdowns should the world’s largest economy experience a second wave of coronavirus infections, which continue to level off as parts of the country reopen.

Coronavirus update: Trump dismisses idea of 2nd wave shutdown; vaccine race heats up

President Donald Trump dismissed the idea of a new series of lockdowns should the world’s largest economy experience a second wave of coronavirus infections, which continue to level off as parts of the country reopen.President Donald Trump dismissed the idea of a new series of lockdowns should the world’s largest economy experience a second wave of coronavirus infections, which continue to level off as parts of the country reopen.

Coronavirus update: Trump dismisses idea of 2nd wave shutdown; vaccine race heats up

Thailand announced on Wednesday that it was developing a vaccine - one of at least 100 potential vaccines in the works worldwide - and hoped to have it into production by next year.Thailand announced on Wednesday that it was developing a vaccine - one of at least 100 potential vaccines in the works worldwide - and hoped to have it into production by next year.

Thailand Begins Coronavirus Vaccine Trials on Monkeys

A quest to find the “magic bullet” is drawing dangerous political lines. Without cooperation, nobody wins.A quest to find the “magic bullet” is drawing dangerous political lines. Without cooperation, nobody wins.

The battle for a Covid vaccine risks losing the “war”

The firm says its experimental mRNA vaccine is safe and induced promising levels of antibodies in a small Phase I clinical trial

Moderna provides cursory glance at first COVID-19 vaccine data

Vaccines will be tested in healthcare workers and communities where the virus is still spreading to show whether they reduced new cases of Covid-19.Vaccines will be tested in healthcare workers and communities where the virus is still spreading to show whether they reduced new cases of Covid-19.

Covid-19: US plans massive coronavirus vaccine testing effort to meet year-end deadline - News | Khaleej Times

Pending the results of a Phase III efficacy trial this summer, a vaccine produced by the biotech company Moderna could be ready for approval as soon as the fall.Pending the results of a Phase III efficacy trial this summer, a vaccine produced by the biotech company Moderna could be ready for approval as soon as the fall.

The Coronavirus Vaccine Is on Track to Be the Fastest Ever Developed | The New Yorker

A new poll from Reuters and Ipsos has found that a quarter of Americans weren't interested in taking a Covid-19 vaccine, which doesn't even exist.Covid-19 has wreaked havoc on the world, causing 5 million recorded infections and 333,000 deaths so far, with a third of the world under lockdown. In orde

A Quarter Of Americans Are Hesitant About Taking A Covid-19 Vaccine That Doesn't Yet Exist | IFLScience

A group of New Zealanders have plans of creating a vaccine for coronavirus using technology created by a Massey University company. A group of New Zealanders have plans of creating a vaccine for coronavirus using technology created by a Massey University company.

Kiwis join quest to find Covid-19 vaccine | 1 NEWS | TVNZ

A coronavirus vaccine might be the door out of this hell. What if our neighbors refuse to walk through it?As the COVID-19 pandemic has unwound around the world and in North Texas, there's been a pot of gold at the end of the rainbow. The only surefire way out of our new confines, according to epidemiologists and public health officials, is researchers finding a vaccine for the novel coronavirus...

What If Texans Won't Get a Coronavirus Vaccine? | Dallas Observer

NK Ganguly, former Director General, ICMR, has said that emergency vaccine for Covid-19 would be available latest by January or February next year.NK Ganguly, former Director General, ICMR, has said that emergency vaccine for Covid-19 would be available latest by January or February next year.

The FDA has approved phase 2 of Moderna's clinical trial to further test their promising vaccine candidate called mRNA-1273.The FDA has approved phase 2 of Moderna's clinical trial to further test their promising vaccine candidate called mRNA-1273.

COVID-19 Vaccine: How Far Along Is The Moderna Vaccine Trial?

A New Zealand company says it's early days, but it's cautiously optimistic about its chances of developing a Covid-19 vaccine.A New Zealand company says it's early days, but it's cautiously optimistic about its chances of developing a Covid-19 vaccine.

wish list